EGCG + PEG-modified liposome

EGCG + PEG-modified liposome (EPL) is a research-stage nanoparticle drug delivery system designed for targeted cancer therapy. The system consists of a liposome surface-modified with polyethylene glycol (PEG) conjugated to (-)-epigallocatechin-3-O-gallate (EGCG), a green tea-derived polyphenol. It encapsulates doxorubicin (DOX) as its primary chemotherapeutic payload. EGCG functions as a dual-purpose component: it acts as a targeting ligand for the 67-kDa laminin receptor (67LR), which is frequently overexpressed in high-grade tumors, and it independently induces apoptosis via caspase-8 activation. The PEGylation of the liposome extends circulation time in the bloodstream, facilitating enhanced accumulation at the tumor site. Preclinical studies in mouse models have demonstrated significant tumor reduction in 67LR-overexpressing cancers through the combined effects of topoisomerase II inhibition by doxorubicin and EGCG-mediated signaling.

Other names

EGCG-PEG-modified liposomeEGCG-PEG-liposomeEGCG-PEG-Lipo-DOX